CIK 0001818382 · Non-accelerated filer<br>Smaller reporting company
Humacyte, Inc.
Sign in to watch- Ticker
- HUMA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851763759
- Phone
- 919-313-9633
- Business address
- 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, NC, 27713
- Former names
- Alpha Healthcare Acquisition Corp.
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market buy Director bought 4,750 shares at $4.18 ($19,855)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 10-K Report Annual Report
- 8-K Event Results of operations
- 8-K Event Regulation FD disclosure
- 4 Option exercise Director acquired 100,000 shares (option exercise)
- 4 Option exercise President, CEO and Director acquired 100,000 shares (option exercise)
- 4 Open-market buy CFO and Chief Corp. Deve. Off. bought 20,000 shares at $2.60 ($52,000)
- 4 Open-market buy President, CEO and Director bought 10,000 shares at $2.54 ($25,400)
- 4 Open-market buy Director bought 10,000 shares at $2.54 ($25,400)
- 4 Open-market sale President, CEO and Director sold 239,538 shares at $2.53 ($606,031)
- 4 Open-market sale Director sold 239,538 shares at $2.53 ($606,031)
- 4 Open-market sale 10% owner sold 239,538 shares at $2.53 ($606,031)
- 4 Open-market buy Chief Commercial Officer bought 5,000 shares at $3.09 ($15,450)
- 4 Open-market sale President, CEO and Director sold 699,730 shares at an average $2.78 ($1,945,509)
Page 15 of 26 · 506 filings